	US 11,945,859 B2
	Protein solution formulation containing high concentration of an anti-VEGF antibody
Juergen Sigg, Loerrach (DE); and Pamela De Moor, Palo Alto, CA (US)
Assigned to NOVARTIS AG, Basel (CH)
Filed by Novartis AG, Basel (CH)
Filed on Dec. 16, 2019, as Appl. No. 16/715,580.
Claims priority of provisional application 62/781,003, filed on Dec. 18, 2018.
Prior Publication US 2020/0190179 A1, Jun. 18, 2020
Int. Cl. A61K 39/395 (2006.01); A61K 9/00 (2006.01); A61K 47/26 (2006.01); C07K 16/22 (2006.01)

CPC C07K 16/22 (2013.01) [A61K 9/0048 (2013.01); A61K 47/26 (2013.01)]

10 Claims

1. An aqueous pharmaceutical composition comprising about 120 mg/ml of an anti-VEGF antibody comprising the sequences of SEQ ID NO: 1 and SEQ ID NO: 2, about 5.8% (w/v) sucrose, 10 mM sodium citrate, and 0.02% (w/v) polysorbate 80, wherein the pH of the composition is 7.2, and wherein the composition does not have an increase in particulate matter counts greater than 10 microns after three days of shaking stress.